Interactions with GluR1 AMPA receptors could influence the therapeutic usefulness of minocycline in ALS
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis Ltd in Amyotrophic Lateral Sclerosis
- Vol. 10 (5-6), 416-417
- https://doi.org/10.3109/17482960802702288
Abstract
Despite the beneficial effects of minocycline seen in animal models of ALS, initial clinical trials of minocycline in ALS patients failed to support its expected therapeutic usefulness. Here we discuss new results from recent preclinical studies of the molecular neuronal effects of minocycline pertinent for better understanding of the therapeutic potential of this antibiotic.Keywords
This publication has 7 references indexed in Scilit:
- Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar ratsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2008
- Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicityEuropean Journal of Neuroscience, 2008
- Minocycline for patients with ALSThe Lancet Neurology, 2008
- Minocycline for patients with ALSThe Lancet Neurology, 2008
- A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.Amyotrophic Lateral Sclerosis, 2008
- Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca2+ signalling in hippocampal neuronsEuropean Journal of Neuroscience, 2007
- Improvement by minocycline of methamphetamine-induced impairment of recognition memory in micePsychopharmacology, 2007